
Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease
The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson
The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson
Last December, Biocat 1 reported that the Bioregion of Catalonia is witnessing a growth in international investment and described Catalonia as a dynamic
Pharmacelera has been awarded an SME Phase I grant from the European Commission for its MolPredict project. The EU received 2009 requests
The Spanish National Research Centre (CNIO) is a Spanish public institution focused on the research, diagnosis and treatment of cancer. The CNIO
For most of the past decade, the number of drugs approved every year per dollar spent on R&D has remained flat or
Image obtained from Advances in Fragment-Based Drug Discovery by Laura Elizabeth Mason Fragment-Based Drug Design (FBDD) is becoming a useful strategy for
We have been working hard to bring up a new Graphical User Interface (GUI) based on feedback from many computational and medicinal
High-Performance Computing (HPC) has become a priority in Europe and it is called to be a strategic resource for the economic competitiveness [1].
Despite the large number of advances in the scientific and technical field underlying the drug discovery process (DNA sequencing, molecular biology, structural
Tautomerism, ionization and chirality are important factors to consider when building a compound library or when finding new hits. Tautomerism and ionization The
Professor Javier Luque (h-index of 66), Pharmacelera’s Scientific Director, has received the 10th edition award from the Boschi Gimpera Foundation for his
Pim-1 is an oncogene-encoded serine/threonine kinase. Originally identified in Maloney murine leukaemia, it is involved in several cellular functions associated with survival
Computational chemistry has been embraced by drug discovery as a key complementary technology to medicinal and organic chemistry [1]. For instance, several
Virtual screening is a well-known approach in drug discovery projects to find new leads in virtual libraries of small molecules, but it
By Alessandro Deplano – Sep. 20, 2017 NOTE: THERE IS A NEW VERSION OF THIS SCRIPT. VISIT THIS PAGE TO DOWNLOAD IT.
Enric Herrero, Pharmacelera’s CTO, is giving a talk about conformation generation at the RDKit User Group Meeting, held in Berlin from Sept